Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Cited In for PubMed (Select 16631222)

1.
2.

Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins.

Dobrowsky TM, Rabi SA, Nedellec R, Daniels BR, Mullins JI, Mosier DE, Siliciano RF, Wirtz D.

Sci Rep. 2013 Oct 22;3:3014. doi: 10.1038/srep03014.

3.

Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B.

Science. 2013 Sep 20;341(6152):1387-90. doi: 10.1126/science.1241475. Epub 2013 Sep 12.

4.

Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet.

Schiavone M, Fiume G, Caivano A, de Laurentiis A, Falcone C, Masci FF, Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Rossi A, Scialdone A, Vecchio E, Andreozzi C, Trovato M, Rafay J, Ferko B, Montefiori D, Lombardi A, Morsica G, Poli G, Quinto I, Pavone V, de Berardinis P, Scala G.

Int J Mol Sci. 2012;13(5):5674-99. doi: 10.3390/ijms13055674. Epub 2012 May 10.

5.

Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Demirkhanyan LH, Marin M, Padilla-Parra S, Zhan C, Miyauchi K, Jean-Baptiste M, Novitskiy G, Lu W, Melikyan GB.

J Biol Chem. 2012 Aug 17;287(34):28821-38. doi: 10.1074/jbc.M112.375949. Epub 2012 Jun 25.

6.

HIV-1 antiretroviral drug therapy.

Arts EJ, Hazuda DJ.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Review.

7.

HIV-1 Entry, Inhibitors, and Resistance.

Lobritz MA, Ratcliff AN, Arts EJ.

Viruses. 2010 May;2(5):1069-105. doi: 10.3390/v2051069. Epub 2010 Apr 29.

8.

Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.

Miyauchi K, Kozlov MM, Melikyan GB.

PLoS Pathog. 2009 Sep;5(9):e1000585. doi: 10.1371/journal.ppat.1000585. Epub 2009 Sep 18.

9.

Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Agrawal-Gamse C, Lee FH, Haggarty B, Jordan AP, Yi Y, Lee B, Collman RG, Hoxie JA, Doms RW, Laakso MM.

J Virol. 2009 Nov;83(21):11005-15. doi: 10.1128/JVI.01238-09. Epub 2009 Aug 19.

10.

Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

Nora T, Bouchonnet F, Labrosse B, Charpentier C, Mammano F, Clavel F, Hance AJ.

Retrovirology. 2008 Feb 29;5:23. doi: 10.1186/1742-4690-5-23.

11.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

13.

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ.

J Virol. 2007 Aug;81(15):8258-69. Epub 2007 May 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk